Trinity Biotech (TRIB) Stock Price, News & Analysis

Company Overview

Trinity Biotech plc (NASDAQ: TRIB) is a global medical diagnostics company focused on developing, manufacturing and marketing products for the management of chronic diseases. The company’s core product lines address diabetes, celiac disease and other autoimmune disorders through a combination of point-of-care analyzers, rapid immunoassays and laboratory-based systems. Trinity Biotech aims to support healthcare professionals with reliable diagnostic tools that facilitate early detection, monitoring and treatment decisions.

In the diabetes market, Trinity Biotech offers a range of hemoglobin A1c (HbA1c) test systems designed for physician offices, clinics and central laboratories. These analyzers provide quantitative results that help assess long-term glucose control. For celiac disease, the company’s portfolio includes enzyme-linked immunosorbent assays (ELISA) and rapid cassette tests that detect disease-specific antibodies. Additionally, Trinity Biotech produces specialty assays for thyroid function, vitamin D and other endocrinological markers, as well as quality controls and calibrators that support laboratory accreditation requirements.

Founded in 1982 and headquartered in Carlsbad, California, with operational facilities in Ireland and strategic offices worldwide, Trinity Biotech serves customers across North America, Europe, Latin America and the Asia-Pacific region. The company’s manufacturing operations adhere to international regulatory standards, including ISO certification and U.S. Food and Drug Administration (FDA) approvals. Trinity Biotech maintains strategic collaborations with research institutions and distribution partners to broaden its market reach and accelerate the launch of new diagnostic solutions.

Under the leadership of Chief Executive Officer Daniel Rowe and an experienced management team, Trinity Biotech continues to invest in research and development to expand its immunoassay platform and enhance product automation. The company places a strong emphasis on clinical validation, regulatory compliance and customer support, positioning itself to address the growing global demand for chronic disease testing and contribute to improved patient outcomes.

Key Stats

• Today's Range: $0.72 to $0.80
• 50-Day Range: $0.55 to $0.85
• 52-Week Range: $0.48 to $3.44
• Volume: 106,458 shs
• Average Volume: 1.11 million shs
• Market Capitalization: $13.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Trinity Biotech Stock Analysis - MarketRank™

Trinity Biotech scored higher than 24% of companies evaluated by MarketBeat, and ranked 845th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Trinity Biotech.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Trinity Biotech are expected to grow in the coming year, from ($1.51) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trinity Biotech is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trinity Biotech is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.33% of the float of Trinity Biotech has been sold short.

Short Interest Ratio / Days to Cover

Trinity Biotech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trinity Biotech has recently increased by 1,668.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Trinity Biotech does not currently pay a dividend.

Dividend Growth

Trinity Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.33% of the float of Trinity Biotech has been sold short.

Short Interest Ratio / Days to Cover

Trinity Biotech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trinity Biotech has recently increased by 1,668.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Trinity Biotech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Trinity Biotech this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Trinity Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trinity Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.20% of the stock of Trinity Biotech is held by insiders.

Percentage Held by Institutions

78.97% of the stock of Trinity Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRIB Stock Analysis - Frequently Asked Questions

How have TRIB shares performed this year?

Trinity Biotech's stock was trading at $0.8802 on January 1st, 2025. Since then, TRIB shares have decreased by 15.8% and is now trading at $0.7413.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech PLC (NASDAQ:TRIB) issued its quarterly earnings results on Monday, May, 24th. The company reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.15. The business had revenue of $25.59 million for the quarter.
Read the conference call transcript.

When did Trinity Biotech's stock split?

Trinity Biotech's stock reverse split on Wednesday, February 21st 2024.The 1-5 reverse split was announced on Wednesday, February 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Trinity Biotech?

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trinity Biotech investors own include Bristol Myers Squibb (BMY), Micron Technology (MU), OPKO Health (OPK), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Pfizer (PFE).

Company Calendar

• Last Earnings: 5/24/2021
• Today: 7/15/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRIB
• CIK: 888721
• Web: www.trinitybiotech.com
• Phone: (531) 276-9800
• Fax: 353-1276-9888
• Employees: 480
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($2.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.79 million
• Net Margins: -68.48%
• Pretax Margin: -49.92%
• Return on Equity: N/A
• Return on Assets: -32.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.28
• Quick Ratio: 0.68

Sales & Book Value

• Annual Sales: $61.56 million
• Price / Sales: 0.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.95) per share
• Price / Book: -0.38

Miscellaneous

• Outstanding Shares: 18,054,000
• Free Float: 16,574,000
• Market Cap: $13.38 million
• Optionable: Optionable
• Beta: 0.80